{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:44:50Z","timestamp":1761864290973,"version":"3.44.0"},"reference-count":19,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,4,19]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>Severe asthma is very difficult to manage in many individuals, and systemic corticosteroids are often used to prevent or manage acute exacerbations. Furthermore, comorbid allergic conditions may render standard therapies inadequate. A 51-year-old man presented with severe eosinophilic asthma requiring nearly constant oral corticosteroid usage despite using high-dose inhaled corticosteroids and secondary asthma controllers. His condition was complicated by aspirin-exacerbated respiratory disease, including severe nasal polyposis, chronic rhinosinusitis, as well as chronic idiopathic urticaria. Mepolizumab was initiated and led to dramatic improvement of asthma over 6 months. However, he continued to experience exacerbations of chronic idiopathic urticaria not responsive to H1-antihistamines. Omalizumab was added, and the patient\u2019s urticaria attained marked improvement with only an occasional breakthrough rash. Dual biologic therapies can be a unique and useful steroid-sparing treatment option for patients with uncontrolled severe asthma and chronic idiopathic urticaria.<\/jats:p>","DOI":"10.1136\/bcr-2021-242211","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T11:19:52Z","timestamp":1621509592000},"page":"e242211","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Dual biologic therapy in a patient with severe asthma and other allergic disorders"],"prefix":"10.1136","volume":"14","author":[{"given":"Joshua Ray","family":"Caskey","sequence":"first","affiliation":[{"name":"Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Section of Allergy\/Immunology, Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"2025082722532778000_14.5.e242211.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2025082722532778000_14.5.e242211.2","unstructured":"Global Initiative for Asthma . Global strategy for asthma management and prevention (2020 update). Global Initiative for Asthma 2020 https:\/\/ginasthma.org\/wp-content\/uploads\/2020\/06\/GINA-2020-report_20_06_04-1-wms.pdf"},{"key":"2025082722532778000_14.5.e242211.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.04.052"},{"key":"2025082722532778000_14.5.e242211.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.11.639"},{"key":"2025082722532778000_14.5.e242211.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"2025082722532778000_14.5.e242211.6","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025082722532778000_14.5.e242211.7","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"The Lancet"},{"key":"2025082722532778000_14.5.e242211.8","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.54"},{"key":"2025082722532778000_14.5.e242211.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.06.010"},{"key":"2025082722532778000_14.5.e242211.10","unstructured":"NUCALA (mepolizumab) injection prescribing information. GlaxoSmithKline LLC, 2015. Available: https:\/\/gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF [Accessed Jan 2021]."},{"key":"2025082722532778000_14.5.e242211.11","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1382"},{"key":"2025082722532778000_14.5.e242211.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2025082722532778000_14.5.e242211.13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-68-5-975"},{"key":"2025082722532778000_14.5.e242211.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.020"},{"key":"2025082722532778000_14.5.e242211.15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025082722532778000_14.5.e242211.16","unstructured":"XOLAIR (omalizumab) injection prescribing information. Genentech USA, Inc. and Novartis pharmaceuticals Corporation, 2003. Available: https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf [Accessed Jan 2021]."},{"key":"2025082722532778000_14.5.e242211.17","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"2025082722532778000_14.5.e242211.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.032"},{"key":"2025082722532778000_14.5.e242211.19","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/eji.201847668","article-title":"Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from Fc\u03b5RI","volume":"48","author":"Maggi","year":"2018","journal-title":"Eur J Immunol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-242211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:53:33Z","timestamp":1756360413000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-242211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,20]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/bcr-2021-242211"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-242211","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}